

## **Cathy S. Cutler, PhD**

Cathy S. Cutler, Ph.D. is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National Laboratory. Dr. Cutler earned the Bachelor of Sciences in Biochemistry in 1988 and a Doctorate in Inorganic Chemistry in 1993 from the University of Cincinnati with the thesis, *Studies at the Interface between Inorganic Chemistry and Nuclear Medicine: Mechanisms of Action of Selected Metal Based Radiopharmaceuticals* under the direction of Dr. Ed Deutsch. Dr. Cutler then joined the Radiation Sciences group at Washington University School of Medicine where she worked under the guidance of Dr. Michael J. Welch where she developed and characterized a Ga-68 brain agent that crosses the intact blood brain barrier; designed studies to determine how *in vivo* metabolism affects compounds distribution, clearance and target selectivity; and collaborated to radiolabel and evaluate peptides containing unique amino acids with modified side chains to bind metals such as technetium, rhenium and rhodium. It was this collaboration that drew Dr. Cutler to the University of Missouri Research Reactor Centers Radiopharmaceuticals Group in 1998. She worked there till June of 2015. The MIRP group at Brookhaven operates the LINAC Isotope Producer (BLIP) that produces both Sr-82 and Ge-68 for commercial production as well as a number of research radioisotopes and is currently evaluating the accelerator production of Ac-225. Additionally, she directs the Target Processing Labs (TPL) that manufactures targets from both the BLIP and isotopes produced off-site for medical applications meeting cGMP. Dr. Cutler's research focuses on developing production and separation methods for high specific activity radioisotopes, creating a suite of diagnostic and therapeutic agents tailored for individual needs which has been funded by the DOE, NIH, NSF and public foundations. She brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.